Trial Profile
Phase II clinical study of GW572016 [lapatinib] in patients with advanced or metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Sep 2009 Actual patient number (67) added as reported by ClinicalTrials.gov.
- 01 Sep 2009 Actual initiation date changed from Mar 2004 to Jun 2004 as reported by ClinicalTrials.gov.
- 01 Sep 2009 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.